Delaware Public Health Lab’s (DPHL) wastewater surveillance testing is using a predictive method to monitor disease for a more rapid public health response for the entire state of Delaware. Currently, the lab is running 35 wastewater samples per week to detect SARS-CoV-2, influenza virus A and B, mpox, and norovirus. They are planning to add Candida auris to their testing library in the near future.

In this study, the Nanotrap® Protein Enrichment Affinity Kit (PEAK) was compared to a magnetic, protein-binding bead-based enrichment kit. Three different healthy human plasma samples were processed using several different Nanotrap® PEAK methods, including the Combined Particle Method, the 2-Particle Method, and the 3-Particle Method.(1) After Nanotrap PEAK enrichment, each sample was digested, cleaned up, and analyzed using LC-MS/MS. Each of the three samples was also processed using off-the-shelf kits for protein enrichment, digestion, and clean-up, and was analyzed using the same settings on the LC-MS/MS. The samples were also processed without protein enrichment as a neat sample. Neat samples were digested, cleaned up, and analyzed using LC-MS/MS. All three of the Nanotrap PEAK methods resulted in more unique protein identifications than the competitor kit’s method for all plasma samples. APPLICATION NOTE SKU 34XXX Lit # PL-AN31399

Wastewater surveillance has become a vital tool for monitoring infectious diseases like COVID-19 at the community level.(1) As microbes continue to mutate, giving rise to variants with differing transmissibility and virulence, tracking the emergence and prevalence of these variants has become a critical component of wastewater-based monitoring. Although PCR-based methods are the gold standard for pathogen detection and quantification, they are generally not designed to distinguish among a broad range of variants. Meanwhile, genomic sequencing—while comprehensive—is often too complex, time-consuming, and resource-intensive for many wastewater testing laboratories.(2) In this study, we developed a customizable digital PCR (dPCR)-based genotyping approach to detect SARS-CoV-2 variants in wastewater.(3) This method provides a rapid and cost-effective way to screen for specific variants, enabling detection of both known and emerging variants beyond predefined markers. We also built a streamlined data analysis pipeline and integrated the results into a public-facing dashboard to deliver real-time insights alongside clinical and GISAID sequencing data. Results from a year-long surveillance effort across Georgia (April 2023–April 2024) highlight the potential of wastewater-based dPCR genotyping as a scalable, timely, and community-representative approach for tracking SARS-CoV-2 variants. POSTER SKU 44XXX

Mass spectrometry-based proteomic analysis of plasma is a vital tool for biomarker discovery, yet it is hindered by high-abundance proteins, which can obscure the detection of low-abundance biomarkers. Nanotrap® Protein Enrichment Affinity Kit (PEAK) is a simple, versatile, and easy-to-use kit that improves the detection of low-abundance proteins from multiple sample types. These kits utilize the Nanotrap® magnetic hydrogel particle technology to enrich low-abundance proteins from complex sample matrices. In this study, three different Nanotrap® Protein Particle types and multiple particle combinations for plasma processing were evaluated. Each of the workflows offers unique benefits, allowing researchers to tailor their approach. Additionally, we investigated whether a simple 30-minute enrichment step using Nanotrap® PEAK would enhance protein identification in plasma, cerebrospinal fluid (CSF), and urine samples. SKU # 34XXX Literature # PL-PO31442

The Driscoll Lab at West Virginia University uses genomics and bioinformatics to track disease agents and understand how they originate and spread from a One Health perspective. The laboratory processes environmental water samples from wastewater, surface water, and large-scale event wastewater on a statewide basis. The main laboratory is located at the West Virginia University campus, but they also have a mobile laboratory for onsite sample preparation, concentration, and extraction, enabling them to process samples much faster. The lab processes approximately 30 samples per week and is currently testing for SARS-CoV-2, RSV, Flu A, Flu B, and norovirus using both a high-throughput automated system and sequencing. The West Virginia University Environmental Water Surveillance team in front of their mobile lab.

The Translational Research Laboratory, which is embedded within the Belfer Center of Applied Cancer Science at Dana-Farber Cancer Institute, researches and clinically tests critical unmet needs in the monitoring of oncology treatment from blood and other routinely clinically accessible tissue not addressed by routine pathology. They track patient response to targeted therapies through minimally invasive sampling of circulating tumor cell-free DNA. Early detection of emerging resistance informs clinicians about changes in tumor phenotypes.

In this study, we demonstrate protein enrichment from human urine samples using the Nanotrap® Protein Enrichment Affinity Kit (PEAK). We processed 1,000 μL each of three different healthy human urine samples using several different manual Nanotrap® PEAK methods, including the Combined Particle Method, the 1-Particle Method, the 2-Particle Method, and the 3-Particle Method.(1) After Nanotrap PEAK enrichment, each sample was digested, cleaned up, and analyzed using LC-MS/MS. Each of the three samples was also processed without protein enrichment as a neat sample. SKU # 34XXX Literature # UR-TN31401

In this study, we demonstrate that the Nanotrap® Protein Enrichment Affinity Kit (PEAK) is compatible with human serum for proteomic analysis. SKU # 34XXX Literature # SR-TN31427

In this study, we demonstrate that the Nanotrap® Protein Enrichment Affinity Kit (PEAK) is compatible with Streck Protein Plus BCT™ for proteomic analysis of human plasma. SKU # 34XXX Literature # PL-TN31428

Abstract Objectives: The growing threat of emerging infectious diseases necessitates proactive genomic surveillance, particularly, in regions with limited resources and low levels of existing reporting. This study highlights the implementation of a comprehensive genomic surveillance program at the Kigali International Airport and explores the utility of a dual-sample strategy leveraging environmental aircraft wastewater and pooled nasal swab sample types for comprehensive detection and characterization of SARS-CoV-2 lineages being imported into Rwanda. Methods: Using a combined pooled nasal swab and aircraft wastewater sampling approach resulted in complementary insights in terms of geographic coverage, positivity, and variant characterization. Results: Mutational profiling in source pooled nasal swabs and aircraft wastewater sample data revealed dynamic shifts in mutation prevalence that corresponded with global patterns. Emerging variant JN.1 was detected early in nasal swab data, demonstrating the power of using genomic surveillance as an early warning system. Conclusions: These results support the feasibility of pathogen surveillance in high-traffic settings and may help drive interest in expanding programs to include pathogens beyond SARS-CoV-2. SKU # 44XXX Misbah Gashegu, Raissa Muvunyi, Jean Pierre Musabyimana, Esperance Umumararungu, Laetitia Irankunda, Chantal Mutezemariya, Arlene Uwituze, Nelson Gahima, John Rwabuhihi, Jean Claude Mugisha, Ayman Ahmed, Noel Gahamanyi, Leon Mutesa, Cecilia A. Prator, Elizabeth A. Landis, Casandra W. Philipson, Nicole Bohme Carnegie, Albert Tuyishime, Isabelle Mukagatare, Noella Bigirimana, Claude Mambo Muvunyi, Early detection of SARS-CoV-2 variants using genomic surveillance: insights from aircraft wastewater and nasal swabs at Kigali International Airport, Rwanda, IJID Regions, Volume 16, 2025, 100678, ISSN 2772-7076, https://doi.org/10.1016/j.ijregi.2025.100678 . (https://www.sciencedirect.com/science/article/pii/S2772707625001134)

Bloodstream infections, such as sepsis, demand rapid and accurate pathogen detection and identification. Conventional blood culture methods are hindered by lengthy incubation times and the requirement for large sample volumes, which limits their utility in critically ill patients. Although molecular assays offer faster turnaround, they are often compromised by high background levels of host DNA, low pathogen titers, and an inability to isolate intact organisms for downstream culturing applications. This study aims to address two key questions: Do Nanotrap® Microbiome B Particles improve the detection sensitivity of bacteria from whole blood relative to current standard extraction methods? Can Nanotrap Microbiome B Particles capture and concentrate gram-positive and gram-negative bacteria from whole blood? SKU# 65XXX Literature # BL-PO31447

Urine has traditionally been overlooked in viral diagnostics, with most research focusing on blood and respiratory samples. Advances in molecular testing and metagenomic sequencing have revealed that urine contains a diverse array of viral targets, including both eukaryotic viruses and bacteriophages. This growing evidence suggests that the urinary virome, much like the gut microbiome, may play a role in maintaining health and influencing disease. Despite these findings, current diagnostic methods, such as molecular assays and culture-based techniques, remain limited by low viral titers, inhibitory matrix components, and lengthy processing times. These challenges continue to hinder the comprehensive characterization of the urinary virome and its clinical relevance. To address these challenges, we evaluated the use of Nanotrap® Microbiome B Particles to concentrate viral and bacterial microbes from urine. This application aims to enhance the detection and analysis of the urinary virome and microbiome across various urine sample volumes in a high-throughput setting. SKU # 65XXX Literature # UR-PO31448